Trial Profile
A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AT 9283 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Sep 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 23 Aug 2018 Planned End Date changed from 30 May 2013 to 1 Dec 2018.